Professor Yongfeng Shang, academician of the Chinese Academy of Sciences, is President of Tianjin Medical University. He is a famous biochemist and molecular biologist in our country, mainly engaging in the research of epigenetic mechanism of the gene transcription and regulation and gynecological neoplasms molecular mechanisms related to sex hormones.
Working in the area of molecular mechanisms he has proposed, tested and interpreted the hypothesis that when estrogen receptor transcribes initiation complex, the combination goes in circle and that the gene transcription mediated by estrogen receptor is both “diphasic” and “bidimensional”, which added something new to the theory of gene transcription and regulation.
He has made a great contribution to the development of the theory of tumor molecular biology by discovering the molecular mechanisms of how the estrogen receptor antagonist, tamoxifen, induce endometrial cancer and cloned multiple tumor-related genes.
He discovered the mechanism of the coordinate role of histone deacetylation and histone demethylation in chromatin remodeling, which have innovative theoretical significance for understanding the molecular mechanism of manifesting epigenetic regulation.
He established the world’s first mammalian cell chromatin immune precipitation technology (ChIP), making an important contribution to the study of the interaction between DNA and proteins.
He has published a series of research papers in Cell, Nature and Science, which won him the honors of “China’s Top Ten News of Basic Research” in 2005, “Ten Technology Advances in Chinese Universities” in 2006, the 1st prize of the “Chinese Medical Science and Technology Award” in 2007, the 1st prize of the “Natural Science Award of Education Ministry” in 2007 and the 2nd prize of the “National Natural Science Award” in 2008. He also obtained the 9th “China Youth Science and Technology Award”, “Lilai Research Award” in 2006 and “He Liang He Li Science and Technology Award” in 2007. He is also the PhD supervisor of national top hundred excellent doctoral dissertations in 2007.
Professor Xianzhong Wu, academician of the Chinese Academy of Engineering, is a renowned expert in both surgery and integrated traditional Chinese medicine and Western medicine. Being a pioneer and an initiator in treating acute abdominal surgical diseases with integrated Chinese and Western medicine, he won the Major Science and Technology Achievement Award in 2007.
Creatively summarizing the guiding principles, the syndrome differentiation and the basic therapy of acute abdomen treatment with the integrated Chinese and Western medicine, Prof. Wu initially advanced the integrative discipline of Chinese and Western medicine to a high level and organized multi-disciplinary collaborative research, thus promoting the development of the integrated Chinese and Western Medicine in both scope and depth.
The research idea of “taking the therapy as a step forward for understanding the treatment principle” put forward by him has deepen the research on the intestinal dredging and purging therapy, heat-clearing and detoxifying, blood-activating and stasis–dissolving, and Qi-promoting and anxiety-relieving treatments, which has simultaneously revolutionized traditional Chinese medicine’s dosage-forms.
The “basic research and application of intestinal dredging and purging therapy in abdominal surgical diseases” presided over by him explained clearly the mechanisms of intestinal dredging and purging therapy in Chinese medicine on the five aspects mainly including increasing bowel movements and increasing abdominal blood circulation, etc. Among 1484 cases of acute intestinal obstruction treatment with intestinal dredging and purging therapy, non-surgical treatment success rate is 80.8% and mortality is 2.7%, which is at a leading level nationally. By combining the intestinal dredging and purging therapy with other treatments, the mortality of severe acute pancreatitis has decreased from 30% to 15%, and that of severe acute cholangitis from 10%-20% to 2%. So far an effective way has been found for the treatment of abdominal inflammatory diseases and the prevention of SIRS/MODS. He has made progressive achievements and innovations in the combination of Chinese and Western medicine for the treatment of abdominal surgical diseases, which won him the 2nd prize of the National Science and Technology Progress Award in 2003.
Professor Xishan Hao, academician of the Chinese Academy of Engineering, is one of the most famous oncology experts bothnationally and internationally. In the year 2010, he won a “Gold Medal” awarded by the Chinese Hepato-Pancreato-Biliary Association.
In 1980s, Professor Hao, firstly used killer cells (LAK) + interleukin (IL-2) sourced from an autologous spleen, which are activated by the lymphoid factor, through perfusion of the hepatic artery to treat liver cancer in location, which offered a new treatment for the mid to late hepatocellular carcinoma patients.
In China, he has taken the lead in doing “high-dose chemotherapy combined with autologous hematopoietic stem cell transplantation to treat solid tumor” and established a series of standard approaches in collecting, preserving and the appraising autologous peripheral blood stem cells, resulting in the largest group of treatment cases nationally with zero correlation mortality. In 2001, he was awarded the 1st prize of the Chinese Medical Science Award.
Under his guidance, the “clinical and basic research of stomach replacement using continuous separate jejunum”, which involves keeping the ends of ing innervated jejunum anastomosed between the esophagus and the duodenum using moderate ligation. This results in a reduction of complications to 74% after total gastric resection. This proved to be a breakthrough in the research into surgical procedures of digestive tract, for which he was awarded the 2nd prize of the National Science and Technology Progress Award in 2001.
He has taken charge of the “current trend analysis and prevention research among urban residents with malignant tumors”, which established the malignant tumor death monitoring system, covering 4 million residents for almost 30 years. This has provided the death data and popular trend parameters of 59 malignancies for our country over the last 20 years. Also, this will provide theoretical references for long-term cancer prevention and control strategy in our country. For this he was awarded the 2nd prize of the National Science and Technology Progress Award in 2006.